John Vandermosten

Raghuram Selvaraju

Ram Raju

- The chronic gout market is expected to maintain **stable growth** over the forecast period of **2025–2034**, driven by increasing prevalence, enhanced diagnosis, and a robust R&D pipeline.  **[1006281_626cee659cb24571aa377e854e4aa8c5_0]** 
- The **United States** accounts for the largest market size of chronic gout compared to EU4, UK, and Japan.  **[1006281_626cee659cb24571aa377e854e4aa8c5_0]** 
- Key companies such as **Sobi, Cartesian Therapeutics, Arthrosi Therapeutics, and Atom Therapeutics** are actively developing innovative chronic gout drugs.  **[1006281_626cee659cb24571aa377e854e4aa8c5_0]** 
- Emerging therapies like **NASP (Sobi/Cartesian Therapeutics)**, **Pozdeutinurad (Arthrosi Therapeutics)**, and **Lingdolinurad (Atom Therapeutics)** are anticipated to enter the market during the forecast period.  **[1006281_626cee659cb24571aa377e854e4aa8c5_1]** 
- **NASP** initiated a rolling Biologics License Application (BLA) submission in **July 2024**, with a regulatory decision expected in **2026**.  **[1006281_626cee659cb24571aa377e854e4aa8c5_2]**  **Pozdeutinurad** is in Phase III trials, achieving key enrollment milestones in **March 2025**.  **[1006281_626cee659cb24571aa377e854e4aa8c5_3]**

Protalix BioTherapeutics (PLX)